Yepes-Núñez Juan José, Gómez Carolina, Espinoza Yeinis, Cardona Ricardo
Grupo Académico de Epidemiología Clínica, Universidad de Antioquia, Medellín, Colombia.
Grupo de Alergología Clínica y Experimental, Universidad de Antioquia, Medellín, Colombia.
Biomedica. 2014 Apr-Jun;34(2):282-90. doi: 10.1590/S0120-41572014000200014.
The prevalence of asthma and allergic rhinitis in Colombia is increasing at the same rate as it is in other parts of the world. It has been determined that allergen-specific subcutaneous immunotherapy is effective in subjects with allergic rhinitis and asthma that are sensitized to house dust mites: Dermatophagoides farinae and Dermatophagoides pteronyssinus .
To provide evidence on changes in the quality of life of subjects induced by allergen-specific subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus .
We selected 76 subjects with a diagnosis of respiratory allergy with sensitization to Dermatophagoides farinae and Dermatophagoides pteronyssinus . The instruments used for evaluating the quality of life were Kidscreen-27 and SF-36. These instruments were applied twice for each subject: once during the first visit, and during the twelfth visit corresponding to the one-year follow-up.
Twenty-two subjects completed this study. After one year of treatment with allergen-specific subcutaneous immunotherapy, we found positive changes in terms of the quality of life. In children, the main change was in the School Environment domain while in adults it was in the Physical Function domain.
We evaluated, for the first time in Colombia, benefits induced by allergen-specific subcutaneous immunotherapy for dust mites in terms of quality of life in subjects with allergic rhinitis and asthma. These results demonstrated that allergen-specific subcutaneous immunotherapy produces a positive influence on subjects sensitized to dust mites that received allergen-specific subcutaneous immunotherapy to Dermatophagoides farinae and Dermatophagoides pteronyssinus after one year.
哥伦比亚哮喘和过敏性鼻炎的患病率与世界其他地区一样呈上升趋势。已确定过敏原特异性皮下免疫疗法对尘螨(粉尘螨和屋尘螨)致敏的过敏性鼻炎和哮喘患者有效。
提供关于粉尘螨和屋尘螨过敏原特异性皮下免疫疗法对患者生活质量影响变化的证据。
我们选择了76例诊断为呼吸道过敏且对粉尘螨和屋尘螨致敏的患者。用于评估生活质量的工具是儿童生活质量量表(Kidscreen - 27)和健康调查简表(SF - 36)。这些工具对每位患者各使用两次:一次在首次就诊时,另一次在对应一年随访的第十二次就诊时。
22例患者完成了本研究。经过一年的过敏原特异性皮下免疫疗法治疗后,我们发现患者的生活质量有积极变化。在儿童中,主要变化体现在学校环境领域;而在成人中,主要变化体现在身体功能领域。
我们在哥伦比亚首次评估了过敏原特异性皮下免疫疗法对尘螨致敏的过敏性鼻炎和哮喘患者生活质量的影响。这些结果表明,对于对粉尘螨和屋尘螨致敏并接受了一年过敏原特异性皮下免疫疗法的患者,该疗法产生了积极影响。